Evaluation of the effect of colchicine in the treatment of patients with COVID-19

Phase 3

Recruiting

• Conditions: Coronavirus disease 2019.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20191104045328N7
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

Patients with COVID-19 infection 16 years and older
Patients admitted to the infectious ward of COVID-19 hospitals in Arak

Exclusion Criteria

Pregnancy and lactation
Existence of liver and kidney disorders
Age less than 16 years

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of hospitalization. Timepoint: After patient discharge. Method of measurement: Days of hospitalization.;Oxygen saturation. Timepoint: The first, third, fifth and seventh day of hospitalization. Method of measurement: Oximeter pulse.;Laboratory findings (complete blood cell count, liver function test, serum urea and creatinine, creatine phosphokinase, serum sodium and potassium levels, blood sugar, serum magnesium level, serum lactate dehydrogenase level, ferritin). Timepoint: The first and seventh day of hospitalization. Method of measurement: Taking a blood sample.